Tubostation A (TA), a specific HDAC6 inhibitor, significantly improved renal function, reduced serum creatinine and blood urea levels, and decreased NGAL expression in rhabdomyolysis-induced AKI [20]. This evidence concerns the gene LCN2 and rhabdomyolysis.